Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Cirrhosis

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    September 2022
  1. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    J Gastroenterol. 2022 Sep 29. pii: 10.1007/s00535-022-01925.
    PubMed     Abstract available


    July 2022
  2. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    PubMed     Abstract available


    May 2022
  3. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    PubMed     Abstract available


    January 2022
  4. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available


    December 2021
  5. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    PubMed     Abstract available


  6. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    PubMed     Abstract available


    November 2021
  7. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    PubMed     Abstract available


    September 2021
  8. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available


    July 2021
  9. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available


    May 2021
  10. ITAKURA J, Kurosaki M, Setoyama H, Simakami T, et al
    Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
    J Gastroenterol. 2021;56:470-478.
    PubMed     Abstract available


    March 2021
  11. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.
    PubMed    


    February 2021
  12. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available


    November 2020
  13. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available


    October 2020
  14. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available


    September 2020
  15. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    PubMed     Abstract available


    August 2020
  16. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    PubMed     Abstract available


    January 2020
  17. KAJI K, Yoshiji H
    Can portal hypertension and hepatic decompensation be predicted?
    J Gastroenterol. 2020 Jan 21. pii: 10.1007/s00535-020-01669.
    PubMed    


    October 2019
  18. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
    Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
    PubMed     Abstract available


    September 2019
  19. KIM D, Kim W, Joo SK, Han J, et al
    Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
    J Gastroenterol. 2019 Sep 18. pii: 10.1007/s00535-019-01628.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: